Lecanemab is a new drug that has shown promise in slowing the progression of Alzheimer's disease by targeting beta amyloid in the brain. While its impact on daily life is debated, it represents a potential breakthrough in Alzheimer's treatment. Regulators in the US are reviewing data for approval, with plans to begin the approval process in other countries. Individuals affected by Alzheimer's, like David and Cheryl, are hopeful for the drug's potential benefits, despite concerns about risks and long-term impact. The Alzheimer's Society calls for a government strategy to address the growing crisis of dementia. The BBC is seeking individuals to share their experiences with Alzheimer's research and related stories.